Cylene Pharmaceuticals Announces New Vice President of Clinical Operations.Business Editors/Health/Medical Writers BIOWIRE2K SAN DIEGO--(BUSINESS WIRE)--April 7, 2004 Cylene Pharmaceuticals Inc., an oncology drug discovery and development company, today announced that John K.C. Lim, Pharm.D., has joined the company as vice president of clinical operations. Dr. Lim brings to Cylene more that 15 years of experience in clinical research and new drug development, principally in the oncology and biotechnology arenas, according to William Rice, Ph.D., president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Cylene. "We are extremely pleased to have Dr. Lim join Cylene," said Dr. Rice. "John will team up with Cylene co-founder Dr. Daniel Von Hoff for the strategic design and execution of our preclinical and clinical development programs, including our recently selected clinical candidate, CX-3543." "I am looking forward to working with John, who brings an enormous wealth of experience and expertise to bear on the clinical development of our compounds," added Dr. Von Hoff. Dr. Lim joined Cylene from US Oncology Research, where he was the vice president for research operations. US Oncology, the country's premier cancer care services company, and its network of research sites has contributed to the development and approval of 18 new cancer agents over the past decade. Prior to joining US Oncology, Dr. Lim held senior operations positions at Covance and Quintiles Quintiles Transnational Corp. is a contract research organization which serves the pharmaceutical, biotechnology and healthcare industries. History Quintiles was founded in 1982 by Dennis Gillings and as of 2007 it has 18,000 employees. , and was active in the development of new drugs from early phase trials through post marketing research. Previously, Dr. Lim held the positions of vice president and general manager for the Oncology Research Network, vice president of the Gastroenterology Research Network, and vice president for International Operations at Theradex, an oncology focused CRO, where he opened offices for the company in the U.K., France and Australia. Dr. Lim earned his Pharmacy degree from the University of Otago The University of Otago (Māori: Te Whare Wānanga o Otāgo) in Dunedin is New Zealand's oldest university with over 20,000 students enrolled during 2006. and his Doctoral degree at the University of Kentucky The University of Kentucky, also referred to as UK, is a public, co-educational university located in Lexington, Kentucky. . Cylene Pharmaceuticals Inc. is a privately-held pharmaceutical company dedicated to the discovery, development and commercialization of first-in-class small molecule drugs to treat life-threatening diseases, with a particular emphasis in oncology. Cylene's pipeline is led by CX-3543, a c-Myc/VEGF Oncogene oncogene Gene that can cause cancer. It is a sequence of DNA that has been altered or mutated from its original form, the proto-oncogene (see mutation). Proto-oncogenes promote the specialization and division of normal cells. Inhibitor which demonstrates potent in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. efficacy in xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, models of human solid tumors and is currently in preclinical development. CX-3543 and other molecules in the pipeline originate from the company's proprietary platform, which directs small molecules at molecular targets that regulate the expression of key oncogenes oncogenes 1. genes carried by tumor viruses that are directly and solely responsible for the neoplastic transformation of host cells. Many oncogenes function after integration into the DNA of the host cell and some up-regulate normal downstream host cell genes to cause neoplasia. . The company is establishing its leadership position in small molecule regulation of oncogene expression by commercializing the pioneering work of two Cylene founders, Professors Laurence Hurley and Daniel Von Hoff. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion